Translational human and equine regenerative medicine in musculoskeletal conditions.

Overview

• This research article discusses the use of horses as models to study human musculoskeletal diseases within a combined human and veterinary medicine framework called “One Health”.
• It focuses on regenerative medicine strategies, including cellular and non-cellular therapies, to repair musculoskeletal tissues affected by conditions like osteoarthritis and tendon injuries in both humans and horses.

Introduction to Translational Regenerative Medicine in Musculoskeletal Conditions

• Translational regenerative medicine aims to apply findings from one species to benefit others, enhancing therapeutic approaches.
• The “One Health” framework promotes integrated research that considers human and animal health interconnectedly.
• Horses are valuable models for human musculoskeletal conditions because of their similar anatomy and function, especially in joints and tendons.

Musculoskeletal Conditions Studied

• Osteoarthritis (OA): A degenerative joint disease causing cartilage breakdown, affecting both humans and horses.
• Tendon disorders: Injuries resulting from high-impact activities or repetitive strain, common in athletes and equine performance animals.
• Both conditions cause pain, reduced mobility, and impaired quality of life.

Regenerative Medicine Therapeutic Strategies

• These therapies aim to promote tissue regeneration and reduce inflammation to restore function.
• Two broad categories of orthobiologics are highlighted:
  • Cellular orthobiologics: Primarily mesenchymal stromal/stem cells (MSCs), which can differentiate into various tissue types and modulate inflammation.
  • Non-cellular orthobiologics: Include platelet-rich plasma (PRP), interleukin-1 receptor antagonist protein, and alpha-2 macroglobulin, all providing growth factors and molecules that support healing.

Applications and Promises of Orthobiologics

• MSCs: Show potential in treating osteoarthritis and tendon injuries across both species by promoting repair and reducing inflammatory responses.
• Non-cellular therapies: Such as PRP, offer growth factors that stimulate tissue healing without using living cells, which can be safer and more accessible.
• Combination therapies leveraging both cellular and non-cellular components may enhance outcomes by addressing multiple aspects of tissue repair.

Challenges and Limitations

• Manufacturing variability: Different production processes lead to inconsistent orthobiologic product quality and efficacy.
• MSC protocols: Lack of standardized methods for isolation, characterization, and application of MSCs, especially in equine medicine, complicates reproducibility and comparison of results.
• Regulatory and public perception issues: Skepticism and regulatory hurdles regarding safety, efficacy, and ethical concerns slow clinical adoption.

Future Directions and Translational Potential

• Standardization: Developing consistent production and quality control standards for orthobiologic products is critical.
• Improved clinical integration: Better protocols and rigorous clinical trials can facilitate wider acceptance and application.
• Combinatory treatments: Integrating cellular and non-cellular orthobiologics may synergistically improve tissue regeneration in both humans and horses.
• Cross-species research benefits: Insights gained from equine models can accelerate advancements in human musculoskeletal regenerative therapies, and vice versa, embodying the “One Health” approach.